Synopsis:

In this episode of Biotech 2050, host Alok Tayi, CEO and co-founder of Vibe Bio, speaks with Dr. Bruce Leuchter, President and CEO of Neurvati Neuroscience. They discuss capital markets, neurology, psychiatry, and Neurvati's work in ultra-rare diseases. Dr. Leuchter shares his journey from clinical training to leadership at Neurvati. The conversation covers the convergence of neurology and psychiatry, advanced technologies in drug development, and addressing unmet medical needs in neuroscience. Join us for insights into the future of biotech and developments in neuroscience.

Biography:

Dr. Bruce Leuchter brings deep-rooted, wide-ranging experience to his role as President and CEO at Neurvati, spanning neuroscience, clinical neuropsychiatry, biotechnology equity research, healthcare investment banking and entrepreneurship. His expertise captures all aspects of building and leading a neuroscience company, and his experiences have generated deep empathy for the patient journey. Across his many roles in the clinic, industry, and beyond, Dr. Leuchter has maintained a passion for knowledge and has aimed to purposefully apply that knowledge to help patients suffering from diseases of the brain and nervous system.

A physician by training and neuropsychiatrist by specialty, Dr. Leuchter completed residency training in Neurology and Psychiatry at New York Presbyterian Hospital and Weill Cornell Medical College and is a Diplomate of the American Board of Psychiatry and Neurology. Dr. Leuchter served as Director of Clinical Neuropsychiatry at Weill Cornell Medical College and maintains a voluntary faculty appointment in the Department of Psychiatry.

Dr. Leuchter has also held multiple financial services roles including biotechnology equity research at Goldman Sachs, healthcare investment banking at Credits Suisse, and biotechnology mergers and acquisitions at PJT Partners, all of which drive a nuanced understanding of the biotechnology industry and particularly the neuroscience ecosystem.

Dr. Leuchter is Co-Founder and Founding Neuropsychiatrist of a digital therapeutics company, Click Therapeutics, which specializes in the treatment of neurological and psychiatric disorders. He serves as a member of the Scientific Advisory Committee for the Daedelus Fund for Innovation at Weill Cornell Medical College, as a member of the Life Science Institute Leadership Council at the University of Michigan, as a member of the Advisory Board at Michigan Drug Discovery, and as a Business Advisory Board member at FOXG1 Research Foundation.